Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $56.2 million.

  • BridgeBio Pharma's Accumulated Expenses rose 2897.04% to $56.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 2897.04%. This contributed to the annual value of $58.3 million for FY2024, which is 167.16% up from last year.
  • Per BridgeBio Pharma's latest filing, its Accumulated Expenses stood at $56.2 million for Q3 2025, which was up 2897.04% from $37.2 million recorded in Q2 2025.
  • BridgeBio Pharma's Accumulated Expenses' 5-year high stood at $58.3 million during Q4 2024, with a 5-year trough of $15.5 million in Q1 2022.
  • Its 5-year average for Accumulated Expenses is $33.4 million, with a median of $32.4 million in 2024.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 17784.33% in 2021, then crashed by 2547.13% in 2022.
  • BridgeBio Pharma's Accumulated Expenses (Quarter) stood at $37.0 million in 2021, then dropped by 15.62% to $31.3 million in 2022, then skyrocketed by 83.55% to $57.4 million in 2023, then grew by 1.67% to $58.3 million in 2024, then fell by 3.73% to $56.2 million in 2025.
  • Its last three reported values are $56.2 million in Q3 2025, $37.2 million for Q2 2025, and $33.4 million during Q1 2025.